Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Byrnes

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Pediatric Research|March 12, 2015
Spatial and temporal patterns in preterm birth in the United StatesJohn Byrnes, Richard Mahoney, Cele Quaintance, et al.
Blood|January 10, 2002
Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter studyPier M Mannucci, Juan Chediak, Wahid Hanna, et al.
American Heart Journal|March 12, 2011
Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacyBarry Trachtenberg, Darcy L Velazquez, Adam R Williams, et al.
Circulation Research|February 26, 2014
Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trialVasileios Karantalis, Darcy L DiFede, Gary Gerstenblith, et al.
JAMA|November 3, 2012
Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trialJoshua M Hare, Joel E Fishman, Gary Gerstenblith, et al.
JAMA|November 20, 2013
Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trialAlan W Heldman, Darcy L DiFede, Joel E Fishman, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Pediatric Research|March 12, 2015
Spatial and temporal patterns in preterm birth in the United StatesJohn Byrnes, Richard Mahoney, Cele Quaintance, et al.
Blood|January 10, 2002
Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter studyPier M Mannucci, Juan Chediak, Wahid Hanna, et al.
American Heart Journal|March 12, 2011
Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacyBarry Trachtenberg, Darcy L Velazquez, Adam R Williams, et al.
Circulation Research|February 26, 2014
Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trialVasileios Karantalis, Darcy L DiFede, Gary Gerstenblith, et al.
JAMA|November 3, 2012
Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trialJoshua M Hare, Joel E Fishman, Gary Gerstenblith, et al.
JAMA|November 20, 2013
Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trialAlan W Heldman, Darcy L DiFede, Joel E Fishman, et al.
Pageof 5